This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: 21/9/2136    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager NURSA Molecule Pages Link Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Zhen, Y. Articles by Gonzalez, F. J. Search for Related Content PubMed PubMed Citation Articles by Zhen, Y. Articles by Gonzalez, F. J. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH

Metabolomic and Genetic Analysis of Biomarkers for Peroxisome Proliferator-Activated Receptor Expression and Activation

Laboratory of Metabolism (Y.Z., K.W.K., C.C., F.J.G.), National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892; and Institute of Pharmacology (J.R.I.), First Faculty of Medicine, Charles University, 128 00 Praha 2, Czech Republic

Address all correspondence and requests for reprints to: Frank J. Gonzalez, Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892. E-mail: fjgonz{at}helix.nih.gov.

Peroxisome proliferator-activated receptor (PPAR) is a nuclear receptor with manifold effects on intermediary metabolism. To define a set of urinary biomarkers that could be used to determine the efficacy of PPAR agonists, a metabolomic investigation was undertaken in wild-type and Ppar-null mice fed for 2 wk either a regular diet or a diet containing the PPAR ligand Wy-14,643 ([4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid), and their urine was analyzed by ultra-performance liquid chromatography coupled with time-of-flight mass spectrometry. Principal components analysis of 6393 accurate mass positive ions revealed clustering as a single phenotype of the treated and untreated Ppar (–/–) mice plus two additional discrete phenotypes for the treated and untreated Ppar (+/+) mice. Biomarkers of PPAR activation were identified from their accurate masses and confirmed by tandem mass spectrometry of authentic compounds. Biomarkers were quantitated from raw chromatographic data using appropriate calibration curves. PPAR urinary biomarkers highly statistically significantly elevated by Wy-14,643 treatment included 11ß-hydroxy-3,20-dioxopregn-4-en-21-oic acid (>3700-fold), 11ß,20-dihydroxy-3-oxopregn-4-en-21-oic acid (50-fold), nicotinamide (>2-fold), nicotinamide 1-oxide (5-fold), 1-methylnicotinamide (1.5-fold), hippuric acid (2-fold), and 2,8-dihydroxyquinoline-ß-D-glucuronide (3-fold). PPAR urinary biomarkers highly statistically significantly attenuated by Wy-14,643 treatment included xanthurenic acid (1.3-fold), hexanoylglycine (20-fold), phenylpropionylglycine (4-fold), and cinnamoylglycine (9-fold). These biomarkers arise from PPAR effects on tryptophan, corticosterone, and fatty acid metabolism and on glucuronidation. This study underscores the power of mass spectrometry-based metabolomics combined with genetically modified mice in the definition of monogenic metabolic phenotypes.

NURSA Molecule Pages Link:

Nuclear Receptors:   PPARα

Ligands:   Pirinixic acid